遺伝子ベクターの世界市場

遺伝子ベクターの世界市場は2030年までに30億米ドルに到達

2024年に15億米ドルと推定される遺伝子ベクターの世界市場は、分析期間2024-2030年にCAGR 12.7%で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプラスミドDNAベクターは、CAGR 15.3%を記録し、分析期間終了時には9億5,910万米ドルに達すると予測されます。アデノウイルスベクターセグメントの成長率は、分析期間中CAGR 9.6%と推定されます。

米国市場は4億570万米ドルと推定、中国はCAGR17.4%で成長すると予測

米国の遺伝子ベクター市場は、2024年に4億570万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億5,570万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは17.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.0％と11.4％と予測されています。欧州では、ドイツがCAGR 10.1%で成長すると予測されています。

世界の遺伝子ベクター市場- 主要動向と促進要因のまとめ

遺伝子治療と遺伝子工学の発展に遺伝子ベクターが不可欠な理由とは？

遺伝子ベクターは現代の遺伝子治療のバックボーンとなっており、遺伝性疾患の修正、免疫反応の増強、治療目的の細胞工学のために標的細胞への遺伝物質の送達を可能にしています。これらのベクターは、改変された遺伝子を宿主細胞に導入するビークルとして機能し、免疫系の拒絶反応を引き起こすことなく効率的な遺伝子発現を保証します。遺伝子ベクターには、主にウイルス性と非ウイルス性の2種類があり、遺伝子導入の効率、安定性、安全性においてそれぞれ異なる利点があります。

アデノ随伴ウイルス（AAV）、レンチウイルス、レトロウイルスなどのウイルス性ベクターは、その高い導入効率と長期にわたる遺伝子発現能力により、遺伝子治療に広く用いられています。脂質ナノ粒子、エレクトロポレーション、ポリマーベースのキャリアを含む非ウイルス性ベクターは、特にRNAベースの治療やCRISPRを介した遺伝子編集において、より安全な代替手段として支持を集めています。個別化治療、がん免疫療法、希少疾患治療の台頭により、遺伝子ベクターは精密ヘルスケアと再生医療に革命を起こす上で重要な役割を果たしています。

遺伝子ベクターの需要を牽引している産業と用途は？

製薬およびバイオテクノロジー部門は遺伝子ベクターの最大の消費者であり、遺伝子治療、細胞治療、ワクチン開発にこれらの送達システムを活用しています。CAR-T細胞療法の急速な拡大により、レンチウイルスベクターやレトロウイルスベクターががん治療用のT細胞を作製するようになり、高品質のベクター製造に対する需要が大幅に増加しています。さらに、遺伝子ベクターは再生医療に不可欠であり、組織修復や臓器再生のための幹細胞改変を促進します。

ヘルスケアにとどまらず、遺伝子組み換え作物や家畜のための農業バイオテクノロジーでも遺伝子ベクターが研究されています。合成生物学の進歩はまた、代謝経路工学に遺伝子ベクターを利用し、バイオ燃料、生分解性プラスチック、高価値バイオマテリアルの生産を可能にしています。遺伝子導入を最適化するためのAI主導のベクター設計と次世代シーケンシング（NGS）の採用が増加しており、研究と商業的応用がさらに加速しています。遺伝子編集と細胞ベースの治療が拡大し続ける中、遺伝子ベクター技術は遺伝子イノベーションの要であり続けると予想されます。

遺伝子ベクター開発における最新の技術進歩とは？

最近の技術進歩により、遺伝子ベクターの効率性、特異性、安全性が大幅に改善されました。最も注目すべきブレークスルーの一つは、次世代AAVベクターの開発です。このベクターは組織向性に優れ、免疫原性が低減されているため、副作用を最小限に抑えた標的遺伝子導入が可能です。さらに、自己増幅RNA（saRNA）ベクターは、ワクチン開発、特にmRNAベースのプラットフォームで人気を集めており、低用量で長時間のタンパク質発現を可能にしています。

非ウイルス性ベクターの領域では、脂質ナノ粒子（LNP）技術がRNA治療薬に革命をもたらし、ワクチンや遺伝子編集アプリケーションで遺伝物質を送達するための高効率でスケーラブルな方法を提供しています。また、AIによるベクター工学は、合成プロモーターの設計を改善し、遺伝子発現の制御を強化し、オフターゲット効果を減少させました。さらに、CRISPRに基づく遺伝子編集の進歩により、周囲のDNA配列を破壊することなく特定の遺伝子変異を選択的に編集できる精密誘導ベクターの開発が可能になりました。これらの技術革新は、遺伝子治療をより安全で、より効果的で、より広く適用できるものにし、遺伝子治療の展望を再構築しています。

遺伝子ベクター市場の成長を促進している要因は？

遺伝子ベクター市場の成長は、遺伝性疾患の有病率の上昇、遺伝子治療への投資の増加、ベクター製造技術の進歩など、いくつかの要因によってもたらされています。LuxturnaやZolgensmaのようなFDA承認の遺伝子治療の成功は、遺伝子ベクターに基づく治療の臨床的可能性を実証し、さらなる研究開発を促しています。さらに、スケーラブルでGMPに準拠したベクター製造への需要が、ウイルスおよび非ウイルスベクター製造を専門とする開発製造受託機関（CDMO）の拡大につながりました。

個別化医療や次世代免疫療法の台頭も、高精度遺伝子導入システムの必要性に拍車をかけています。規制当局が遺伝子治療の迅速な承認経路を導入したことで、製薬会社は高度なベクター開発に投資するようになりました。さらに、ベクターの最適化におけるAIと計算モデリングの統合は、効率を高め、生産コストを削減しています。腫瘍学、神経学、希少疾患において遺伝子治療の需要が高まり続けていることから、遺伝子ベクター市場は持続的な成長を遂げ、遺伝子医療とバイオ医薬品イノベーションの未来を形成していくと予想されます。

セグメント

ベクタータイプ（プラスミドDNAベクター、アデノウイルスベクター、アデノ随伴ウイルスベクター、レトロウイルスベクター、レンチウイルスベクター、その他のベクタータイプ）、疾患（がん、遺伝子疾患、感染症、その他の疾患）、用途（遺伝子治療用途、ワクチン療法用途、その他の用途）、最終用途（CDMOS最終用途、製薬・バイオテクノロジー企業最終用途、研究機関最終用途、CRO最終用途）

調査対象企業の例

• 4D Molecular Therapeutics
• BioMarin Pharmaceutical Inc.
• Bluebird Bio
• Catalent Biologics
• Charles River Laboratories International Inc
• CRISPR Therapeutics AG
• Editas Medicine
• FUJIFILM Holdings Corporation
• Generation Bio
• Intellia Therapeutics
• Kaneka Corporation
• Lonza Group AG
• Merck KGaA
• Novartis AG
• Oxford Biomedica plc
• Rocket Pharmaceuticals
• Sarepta Therapeutics
• Thermo Fisher Scientific Inc.
• uniQure N.V.
• WuXi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gene Vector Market to Reach US$3.0 Billion by 2030

The global market for Gene Vector estimated at US$1.5 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2024-2030. Plasmid DNA Vector, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$959.1 Million by the end of the analysis period. Growth in the Adenoviral Vector segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$405.7 Million While China is Forecast to Grow at 17.4% CAGR

The Gene Vector market in the U.S. is estimated at US$405.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$655.7 Million by the year 2030 trailing a CAGR of 17.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.

Global Gene Vector Market - Key Trends & Drivers Summarized

Why Are Gene Vectors Essential for Advancing Gene Therapy and Genetic Engineering?

Gene vectors have become the backbone of modern gene therapy, enabling the delivery of genetic material into target cells to correct genetic disorders, enhance immune responses, or engineer cells for therapeutic purposes. These vectors serve as vehicles that transfer modified genes into host cells, ensuring efficient gene expression without triggering immune system rejection. The two primary types of gene vectors-viral and non-viral-offer distinct advantages in gene transfer efficiency, stability, and safety.

Viral vectors, such as adeno-associated viruses (AAVs), lentiviruses, and retroviruses, are widely used in gene therapy due to their high transduction efficiency and long-term gene expression capabilities. Non-viral vectors, including lipid nanoparticles, electroporation, and polymer-based carriers, have gained traction as safer alternatives, particularly for RNA-based therapies and CRISPR-mediated gene editing. With the rise of personalized medicine, cancer immunotherapies, and rare disease treatments, gene vectors are playing a critical role in revolutionizing precision healthcare and regenerative medicine.

Which Industries and Applications Are Driving Demand for Gene Vectors?

The pharmaceutical and biotechnology sectors are the largest consumers of gene vectors, leveraging these delivery systems for gene therapy, cell therapy, and vaccine development. The rapid expansion of CAR-T cell therapies, which rely on lentiviral and retroviral vectors to engineer T cells for cancer treatment, has significantly increased demand for high-quality vector manufacturing. Additionally, gene vectors are essential in regenerative medicine, where they facilitate stem cell modification for tissue repair and organ regeneration.

Beyond healthcare, gene vectors are being explored in agricultural biotechnology for genetically engineered crops and livestock. Advances in synthetic biology are also utilizing gene vectors for metabolic pathway engineering, enabling the production of biofuels, biodegradable plastics, and high-value biomaterials. The increasing adoption of AI-driven vector design and next-generation sequencing (NGS) for optimizing gene delivery has further accelerated research and commercial applications. As gene editing and cell-based therapies continue to expand, gene vector technology is expected to remain a cornerstone of genetic innovation.

What Are the Latest Technological Advancements in Gene Vector Development?

Recent technological advancements have significantly improved gene vector efficiency, specificity, and safety. One of the most notable breakthroughs is the development of next-generation AAV vectors with enhanced tissue tropism and reduced immunogenicity, allowing for targeted gene delivery with minimal side effects. Additionally, self-amplifying RNA (saRNA) vectors are gaining popularity in vaccine development, particularly in mRNA-based platforms, offering prolonged protein expression with lower doses.

In the realm of non-viral vectors, lipid nanoparticle (LNP) technology has revolutionized RNA therapeutics, providing a highly efficient and scalable method for delivering genetic material in vaccines and gene editing applications. AI-driven vector engineering has also improved the design of synthetic promoters, enhancing gene expression control and reducing off-target effects. Furthermore, advances in CRISPR-based gene editing have enabled the development of precision-guided vectors that can selectively edit specific genetic mutations without disrupting surrounding DNA sequences. These innovations are reshaping the gene vector landscape, making gene therapy safer, more effective, and more widely applicable.

What Factors Are Fueling the Growth of the Gene Vector Market?

The growth in the gene vector market is driven by several factors, including the rising prevalence of genetic disorders, increasing investment in gene therapy, and advancements in vector manufacturing technology. The success of FDA-approved gene therapies, such as Luxturna and Zolgensma, has demonstrated the clinical viability of gene vector-based treatments, prompting further research and development. Additionally, the demand for scalable and GMP-compliant vector production has led to the expansion of contract development and manufacturing organizations (CDMOs) specializing in viral and non-viral vector manufacturing.

The rise of personalized medicine and next-generation immunotherapies has also fueled the need for high-precision gene delivery systems. Regulatory agencies have introduced accelerated approval pathways for gene therapies, encouraging pharmaceutical companies to invest in advanced vector development. Furthermore, the integration of AI and computational modeling in vector optimization has enhanced efficiency and reduced production costs. As the demand for gene therapy continues to rise across oncology, neurology, and rare diseases, the gene vector market is expected to experience sustained growth, shaping the future of genetic medicine and biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Gene Vector market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector, Other Vector Types); Diseases (Oncology, Genetic Disorders, Infectious Diseases, Other Diseases); Application (Gene Therapy Application, Vaccinology Application, Other Applications); End-Use (CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use, CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• 4D Molecular Therapeutics
• BioMarin Pharmaceutical Inc.
• Bluebird Bio
• Catalent Biologics
• Charles River Laboratories International Inc
• CRISPR Therapeutics AG
• Editas Medicine
• FUJIFILM Holdings Corporation
• Generation Bio
• Intellia Therapeutics
• Kaneka Corporation
• Lonza Group AG
• Merck KGaA
• Novartis AG
• Oxford Biomedica plc
• Rocket Pharmaceuticals
• Sarepta Therapeutics
• Thermo Fisher Scientific Inc.
• uniQure N.V.
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Gene Vector - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rapid Growth of Gene Therapy and Vaccine Pipelines Drives Demand for High-Quality Gene Vectors
  • Increased Adoption of Viral Vectors for In Vivo Delivery Fuels Development of AAV, Lentivirus, and Adenovirus Platforms
  • Non-Viral Vectors Gain Traction Amid Safety Concerns and Manufacturing Challenges with Viral Vectors
  • OEM Focus on Enhancing Vector Yield, Stability, and Tropism Improves Therapeutic Delivery Outcomes
  • Rise in Genetic Disorders, Cancer Immunotherapies, and Rare Disease Programs Expands Application Scope for Gene Vectors
  • Regulatory Approval of First Commercial Gene Therapies Validates Clinical Potential and Market for Vectors
  • Investment in Vector Manufacturing Capacity and GMP-Grade Platforms Accelerates Global Supply Chain Development
  • Collaborations Between Biotech and CDMOs Enhance Process Development and Scale-Up Capabilities
  • Increased Demand for Custom Vector Engineering Fuels Innovation in Tissue-Specific and Inducible Expression Vectors
  • Shift Toward Synthetic and Modular Vector Platforms Supports Scalability and Cross-Therapeutic Use
  • Advancements in Vector Characterization, Quality Control, and Analytical Testing Improve Regulatory Compliance
  • OEM Integration of AI and Predictive Modeling Supports Rational Vector Design and Functional Optimization
  • Surge in mRNA and DNA-Based Vaccine Development Creates Synergies with Lipid and Polymer-Based Vectors
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gene Vector Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gene Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Plasmid DNA Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Plasmid DNA Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Plasmid DNA Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Adenoviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Adenoviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Adenoviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adeno-Associated Viral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adeno-Associated Viral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adeno-Associated Viral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retroviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retroviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retroviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Lentiviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Lentiviral Vector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Lentiviral Vector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Vector Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Gene Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Vaccinology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Vaccinology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Vaccinology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for CDMOS End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for CDMOS End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for CDMOS End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 56: USA Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 92: China Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Gene Vector by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 119: France Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 155: UK Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Gene Vector by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 230: India Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Gene Vector by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Gene Vector by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Gene Vector by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Gene Vector by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Gene Vector Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Gene Vector by Vector Type - Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Gene Vector by Vector Type - Percentage Breakdown of Value Sales for Plasmid DNA Vector, Adenoviral Vector, Adeno-Associated Viral Vector, Retroviral Vector, Lentiviral Vector and Other Vector Types for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Gene Vector by Diseases - Other Diseases, Oncology, Genetic Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Gene Vector by Diseases - Percentage Breakdown of Value Sales for Other Diseases, Oncology, Genetic Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Gene Vector by Application - Gene Therapy Application, Vaccinology Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Gene Vector by Application - Percentage Breakdown of Value Sales for Gene Therapy Application, Vaccinology Application and Other Applications for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Gene Vector by End-Use - CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Gene Vector by End-Use - Percentage Breakdown of Value Sales for CDMOS End-Use, Pharma & Biotech Companies End-Use, Research Institutes End-Use and CROs End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION